デンバー–(BUSINESS WIRE)–（ビジネスワイヤ） — ネットクラッカー/CSGは、2027 State of the Customer Experience Report（2027年版顧客体験レポート）を発表しました。このレポートでは、顧客がブランドと関わる際に費やす時間、手順、そして精神的負担の増大が、信頼とロイヤルティを損なっていることが明らかになりました。調査結果によると、顧客は、タッチポイントをより迅速かつ容易にし、チャネル間の一貫性を維持し、必要に応じてスタッフによるサポートを引き続き提供しているブランドに留まる傾向があります。 負担増大の弊害の一つとして、「シャドウ カスタマー エクスペリエンス」と呼ばれるプロセスの台頭が挙げられます。これは、顧客がブランドとのやり取りを円滑に進めるためにサードパーティ製AIアシスタントやパーソナルエージェントを利用するようになり、重要なタッチポイントがブランドの管理下から離れてしまう現象です。サポートプロセスが自社チャネルから外れるケースが増えるにつれ、ブランドは可視性、コンテキスト、そして信頼構築の機会を失うリスクに
Month: October 2026
DENVER–(BUSINESS WIRE)–Netcracker / CSG ® oggi ha pubblicato il 2027 State of the Customer Experience Report, secondo il quale la “effort inflation” (Inflazione dello sforzo), ossia la sempre maggiore quantità di tempo, fasi e sforzo mentale impiegati dai clienti per interagire con i marchi sta danneggiando la fiducia e la fedeltà. I risultati dello studio indicano che i clienti rimangono fedeli ai marchi che facilitano e accelerano i punti di contatto con il cliente, assicurando la continuit
DENVER–(BUSINESS WIRE)–Netcracker/CSG® publiceerde vandaag de 2027 State of the Customer Experience Report, waarin wordt vastgesteld dat “inspanningsinflatie”, de toenemende tijd, stappen en geestelijke inspanning die klanten moeten aanwenden om zich bij merken betrokken te voelen, het vertrouwen en de getrouwheid aantast. De bevindingen tonen aan dat klanten bij merken blijven die sneller en makkelijker raakpunten maken, continuïteit in hun kanalen verzekeren en indien nodig toegang tot mens
丹佛–(BUSINESS WIRE)–(美國商業資訊)– Netcracker / CSG®今天發表《2027年顧客體驗狀況報告》(2027 State of the Customer Experience Report)。該報告發現，「顧客心力通膨」(Effort Inflation)，也就是顧客與品牌互動時必須付出的時間、步驟及心思不斷增加，已危及顧客的信任與忠誠度。該研究結果顯示，如果品牌能讓各個接觸點的互動更加快捷簡便，確保跨渠道體驗的連貫性，並在顧客有需要的時候提供人力支援，顧客便有更高的意願繼續選購這些品牌。 「顧客心力通膨」的後果之一，是出現「影子顧客體驗」(shadow customer experience)，意思是顧客求助第三方人工智慧助理或個人代理，由它們來處理與品牌間的互動，導致關鍵接觸點脫離品牌的掌控。若是轉移到品牌自有渠道之外的互動越來越多，品牌將面臨失去洞察力、脈絡以及建立信任機會的風險。這一趨勢突顯確保體驗連貫且省力的必要。這麼做方能跨渠道保持脈絡一致、迅速解決問題，進一步提高顧客忠誠度。 Netcracker/CSG在訪調全球1800位數位公民後
DENVER–(BUSINESS WIRE)–Netcracker/CSG® a publié aujourd’hui le 2027 State of the Customer Experience Report, qui révèle que l’« inflation de l’effort » – c’est-à-dire l’augmentation du temps, du nombre d’étapes et de l’effort mental nécessaires aux clients pour interagir avec les marques – nuit à la confiance et à la fidélité. Les conclusions montrent que les clients resteront fidèles aux marques qui rendent les points de contact plus rapides et plus faciles, garantissent la continuité entre
丹佛–(BUSINESS WIRE)–(美国商业资讯)– Netcracker / CSG ® 今日发布《2027年客户体验现状报告》。报告发现，客户与品牌打交道时，需要花费更多时间、经历更多步骤、耗费更多心力。这种“费力度上升”（Effort Inflation）现象正在损害客户的信任与忠诚度。研究表明，如果品牌能让各个服务环节更快捷、更便捷，确保不同渠道之间顺畅衔接，并在客户需要时提供人工支持，就能留住客户。 费力度上升催生了一种“影子客户体验”——客户借助第三方AI助手和个人智能体与品牌交互，导致关键互动环节脱离品牌掌控。越来越多的求助过程发生在品牌自有渠道之外，品牌可能因此难以掌握客户情况、了解相关背景，也会失去建立信任的机会。这一趋势表明，品牌更需要让各个服务环节顺畅衔接，在客户切换渠道时保留相关信息，快速解决问题，以省心的体验增强客户忠诚度。 Netcracker/CSG对全球1,800名“数字公民”的调查发现： 客户寻求帮助越来越费力：74%的消费者表示，与一年前相比，请品牌解决问题所需付出的精力没有减少，甚至有所增加。五分之一的消费者近期曾因解决过程太费力而放弃处
Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET
PRINCETON, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2026 financial results on Wednesday, November 4th, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and our second product for adult patients with recurrent LG-IR-NMIBC, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.
INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083
MINNEAPOLIS, Oct. 27, 2026 (GLOBE NEWSWIRE) — Clearfield, Inc. (NASDAQ: CLFD), a leader in fiber connectivity solutions for telecom, data center, and network infrastructure environments, today announced that it will release results for the fourth quarter of fiscal 2026, ended September 30, 2026, on Tuesday, November 10th, 2026, after the close of the market. The company will host a conference call at 5:00 p.m. Eastern time (4:00 p.m. Central time) to discuss its financial results with the investment community.
Financial results will be available on the Investor Relations section of the company’s website along with a shareholder letter.
Date: Tuesday, November 10, 2026
Time: 5:00 p.m. Eastern time (4:00 p.m. Central time)
U.S. dial-in: 1-844-501-2063
International dial-in: 1-412-365-5136
The conference call will be webcast live and available for replay here.
An audio replay of the call will be available after 8:00 p.m. Eastern time on the same day through November 24, 2026.
U.S. replay dial-in: 1-844-512-2921
International replay dial-in: 1-412-317-6671
Replay ID: 10212806
About Clearfield, Inc.
Clearfield, Inc. (NASDAQ: CLFD) designs, manufactures, and distributes fiber optic management, protection, and delivery solutions that enable high-performance connectivity across a wide range of markets, helping to close the digital divide. Clearfield’s labor lite, craft-friendly platform is leveraged by community broadband providers, MSOs, incumbent service providers, ISPs, data centers, wireless providers, IoT networks, the military, municipalities, and cooperatives to connect homes, businesses, and critical infrastructure faster and more efficiently. Headquartered in Minneapolis, MN, Clearfield deploys more than a million fiber ports each year. For more information, visit www.SeeClearfield.com.
Investor Relations Contact: Greg McNiff
The Blueshirt Group
773-485-7191
clearfield@blueshirtgroup.com
Source: Clearfield, Inc.
SARASOTA, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) — INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the establishment, acquisition and operation of fertility clinics and related businesses and technologies, announced today that it will effect a 1-for-4 reverse split of its issued and outstanding and of its authorized common stock effective as of 12:01 a.m. Eastern Time on October 30, 2026. Commencing with the opening of trading on The Nasdaq Capital Market on October 30, 2026, the Company’s common stock will trade on a post-split basis under the same trading symbol, “IVF”.
As a result of the reverse stock split, the CUSIP number for the Company’s common stock will be 44984F872. As a result of the reverse stock split, every 4 shares of issued and outstanding common stock will be exchanged for 1 share of common stock. Registered holders of record who would otherwise hold a fractional share will be rounded up to the next whole share. Beneficial holders holding shares in street name through a broker or nominee who would otherwise be entitled to receive a fractional share will receive a cash payment for such fractional interest, the amount of which will be determined and administered by the applicable broker or nominee in accordance with their standard procedures. Immediately after the reverse stock split becomes effective, the company will have approximately 1,192,841 shares of common stock issued and outstanding. In addition, a proportionate adjustment will be made to the company’s authorized shares of common stock such that the Company shall have 62,500,000 shares of authorized common stock after the effective time of the reverse stock split.
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on U.S.-based, profitable fertility clinics. Our clinics offer a variety of fertility services, including in vitro fertilization (“IVF”) and the intravaginal culture (“IVC”) enabled by our INVOcell®. We have four fertility clinics in the United States. We also continue to engage in the sale and distribution of our INVOcell technology solution into third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. For more information, please visit www.invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
NEW YORK–(BUSINESS WIRE)—- $COMP #ClassActionLawsuit–If you have suffered a loss on your Compass, Inc. (“Compass” or the “Company”) (NYSE: HOUS) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until December 7, 2026 to ask the Court to appoint them as lead plaintiff.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]What Is The Lawsuit About?